Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
Sponsor: Novartis Pharmaceuticals
Summary
The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
Official title: A Participant- and Investigator--Blinded, Placebo- Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
112
Start Date
2025-11-20
Completion Date
2027-07-19
Last Updated
2026-03-23
Healthy Volunteers
Yes
Conditions
Interventions
OJR520
Participants will receive OJR520 in different dose levels.
Placebo
Participants will receive OJR520 matching placebo.
Locations (2)
Quotient Sciences Sea View
Miami, Florida, United States
Novartis Investigative Site
Berlin, Germany